• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Participating Faculty

Publication
Article
Supplements and Featured PublicationsSecondary Prevention of Noncardioembolic Ischemic Stroke
Volume 14
Issue 7 Suppl

Secondary Prevention of Noncardioembolic Ischemic Stroke This supplement to The American Journal of Managed Care provides information on the epidemiology, symptoms, risk factors, burden, and treatment options related to noncardioembolic ischemic stroke and transient ischemic attack, with particular focus on secondary prevention of recurrent stroke using antiplatelet agents.

It is the policy of The American Journal of Managed Care to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

In accordance with the ACCME, participants for this activity have completed conflict-of-interest statements.

Jeffrey D. Dunn, PharmD, MBA

Faculty

SelectHealth

Marc Fisher, MD

Department of Neurology

University of Massachusetts Memorial Medical Center

Professor and Vice Chair

Vanderbilt Stroke Center

These participants report relationships with the following corporate organizations:

Consultant:

Consultant/Speakers’ bureau:

Investigator/Speakers’ bureau/Consultant:

Investigator/Speakers’ bureau:

GOA

L

This educational activity is intended for managed care professionals (medical directors and pharmacy directors plus other key personnel in HMOs, PPOs, IHOs, group practices, hospitals, nursing homes, home healthcare, the government [including the Centers for Medicare & Medicaid Services], and employer-based groups).

EDUCATIONAL OBJECTIVES

Release Date: June 30, 2008.

This publication was made possible by an educational grant from Boehringer Ingelheim.

The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

© 2024 MJH Life Sciences
AJMC®
All rights reserved.